Get the Stockscreener App
40.69
1.19%
-0.49
Monopar Therapeutics Inc stock is traded at $40.69, with a volume of 35,807.
It is down -1.19% in the last 24 hours and up +21.25% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$41.18
Open:
$41.6
24h Volume:
35,807
Relative Volume:
1.00
Market Cap:
$248.83M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-17.69
EPS:
-2.3
Net Cash Flow:
$-6.82M
1W Performance:
-9.52%
1M Performance:
+21.25%
6M Performance:
-7.40%
1Y Performance:
+5,770%
1-Day Range:
$39.61
$41.60
1-Week Range:
$39.61
$44.58
52-Week Range:
$0.3438
$54.30
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
40.69 | 251.82M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
What makes Monopar Therapeutics Inc. stock price move sharplySwing Candidate List with Trade Cues - Newser
Will Monopar Therapeutics Inc. price bounce be sustainableFree Sector Based Breakout Stock Forecast - Newser
Monopar Therapeutics Inc. stock trend outlook and recovery pathAI Trading Forecast Based on Big Data - Newser
Is it too late to sell Monopar Therapeutics Inc.Stock Entry Point Planner with Volume Spike - Newser
What are Monopar Therapeutics Inc. company’s key revenue driversDaily Trading Picks Backed By Experts - jammulinksnews.com
Why is Monopar Therapeutics Inc. stock attracting strong analyst attentionEarnings Report Alerts With Proven Results - jammulinksnews.com
Monopar Therapeutics (MNPR) Projected to Post Earnings on Friday - Defense World
Combining price and volume data for Monopar Therapeutics Inc.Technical Screener for High Growth Stocks - Newser
When is Monopar Therapeutics Inc. stock expected to show significant growthStock Strategy Trend Scanner For Every Investor - jammulinksnews.com
Using economic indicators to assess Monopar Therapeutics Inc. potentialFree AI Screening for Swing Trade Picks - Newser
What’s next for Monopar Therapeutics Inc. stock price2-Day Signal Watch with Forecast Outcome - Newser
Will Monopar Therapeutics Inc. stock go up soonFree Triple Digit Growth Focused Trade Plan - Newser
What are the latest earnings results for Monopar Therapeutics Inc.Daily Trading Entry Points For Every Investor - jammulinksnews.com
How volatile is Monopar Therapeutics Inc. stock compared to the marketValue Investing Picks For Beginners - jammulinksnews.com
Is it the right time to buy Monopar Therapeutics Inc. stockTop Growth Signals From AI Tools - jammulinksnews.com
How does Monopar Therapeutics Inc. generate profit in a changing economyWealth Building Review That Work - jammulinksnews.com
Should I hold or sell Monopar Therapeutics Inc. stock in 2025Beginner Investor Ideas For Smart Trading - jammulinksnews.com
When is the best time to buy Monopar Therapeutics Inc. stockFree Breakout Entry Signal Confirmation Tool - Newser
Published on: 2025-07-30 05:23:05 - Newser
Is Monopar Therapeutics Inc. showing signs of accumulationAI Entry Timing Prediction for Swing Traders - Newser
Will a bounce in CLSK offer an exitFree Alpha Driven Watchlist With Alerts - Newser
Short interest data insights for Monopar Therapeutics Inc.Free Low Risk Equity Screener With Results - Newser
RSI Reset May Fuel Rebound in Monopar Therapeutics Inc.Triple Digit Growth Focused Trade Plan Reviewed - metal.it
How Efficient Is Monopar Therapeutics Inc. at Controlling Operating CostsEntry Zone Strategy for Consistent Profit Shared - metal.it
What analysts say about Monopar Therapeutics Inc. stock outlookFree Growth Based Investment Plan Guidance - Newser
What is the dividend policy of Monopar Therapeutics Inc. stockRetirement Planning Entry Points For Consistent Profits - jammulinksnews.com
Does Monopar Therapeutics Inc. stock perform well during market downturnsAchieve superior capital gains with smart trades - jammulinksnews.com
How strong is Monopar Therapeutics Inc. company’s balance sheetSuperior returns - jammulinksnews.com
What are analysts’ price targets for Monopar Therapeutics Inc. in the next 12 monthsInvest confidently with professional guidance - jammulinksnews.com
What is the risk reward ratio of investing in Monopar Therapeutics Inc. stockMaster stock selection with insider knowledge - jammulinksnews.com
How many analysts rate Monopar Therapeutics Inc. as a “Buy”Invest confidently with real-time data analysis - jammulinksnews.com
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monopar Therapeutics Inc Stock (MNPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STARR CHRISTOPHER M | Director |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
5,173 |
| Robinson Chandler | Chief Executive Officer |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
73,472 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):